No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML

A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relap...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer cell Vol. 35; no. 3; pp. 337 - 339
Main Authors:	Thomas, Rozario, Majeti, Ravindra
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 18-03-2019
Subjects:	Humans Leukemia, Myeloid, Acute Mutation RNA-Binding Proteins - genetics Spliceosomes Sulfonamides
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relapsed or refractory to standard therapy. A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relapsed or refractory to standard therapy.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Commentary-1
ISSN:	1535-6108 1878-3686
DOI:	10.1016/j.ccell.2019.02.013